Search API

0 min read

Merck today announced positive data from multiple Phase 3 studies evaluating V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine.

Across the clinical studies presented at the 13th Meeting of the International Society of Pneumonia and Pneumococcal Diseases in Cape Town, South Africa, on March 19, 2024, V116 was shown to be immunogenic for all 21 serotypes covered by the vaccine in a variety of adult populations, including those who had not previously received a pneumococcal vaccine (pneumococcal vaccine-naïve), those who had previously received a pneumococcal vaccine (pneumococcal vaccine-experienced) and those with an increased risk of pneumococcal disease, including people living with human immunodeficiency virus.

In all STRIDE studies presented at the meeting, V116 also elicited higher immune responses than the studied comparators for the serotypes unique to V116.

Several studies presented today were included in the filing submission to the U.S. Food and Drug Administration (FDA). The FDA granted V116 priority review with a Prescription Drug User Fee Act of June 17, 2024.

If approved by the FDA, V116 would be the first pneumococcal conjugate vaccine specifically designed for adults. 

Vaccine Treats: 
Image: 
Image Caption: 
by Pete Linforth
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
0 min read

The journal Vaccines recently published a Short Communication that presented a benefit–risk assessment for the Novavax COVID-19 protein-based vaccine (NVX-CoV2373).

Published on March 16, 2024, this analysis used data on myocarditis/pericarditis cases observed in the NVX-CoV2373 clinical studies, real-world data of mRNA COVID vaccine effectiveness against predominant SARS-CoV-2 strains in early 2023, and recent COVID-19 burden of disease data from the U.S.

The benefits of NVX-CoV2373 vaccination were estimated as the number of COVID-19 cases, hospitalizations, and deaths prevented. The risks of myocarditis/pericarditis cases and related hospitalizations and deaths occurring within seven days of vaccination were also estimated.

In our analysis, vaccination with NVX-CoV2373, per 100,000 vaccinated, prevented an estimated 1805 COVID-19 cases, compared with an estimated 5.3 excess myocarditis/pericarditis cases.

The number of COVID-19 hospitalizations and deaths prevented were also greater than vaccine-associated myocarditis/pericarditis hospitalizations and deaths.

Our analysis indicates a positive benefit–risk balance for NVX-CoV2373, concluded these researchers.

In October 2023, the U.S. Food and Drug Administration amended the EUA of the Novavax COVID-19 Vaccine, Adjuvanted (Nuvaxovid™ XBB.1.5) for use in individuals 12 and older, to include the 2023-2024 formula. 

In the U.S., the current Novavax COVID‑19 Vaccine is available at certain pharmacies, including Costco, CVS Pharmacy, Giant, Publix, Rite Aid, and Stop & Shop.

Vaccine Treats: 
Image: 
Image Caption: 
from Pixabay
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 
measles vaccine
CDC Health Alert Network CDCHAN-00504 - Measles Outbreaks in March 2024
BCG vaccine 2024
World Tuberculosis Day 2024 includes positive investment case for expanding TB screening and preventive treatments
0 min read

The U.S. Centers for Disease Control and Prevention (CDC) and the World Health Organization say the increased number of measles outbreaks is a global threat in 2024.

As of March 14, 2024, a total of 58 measles cases were reported by 17 U.S. jurisdictions: Arizona, California, Florida, Georgia, Illinois, Indiana, Louisiana, Maryland, Michigan, Minnesota, Missouri, New Jersey, New York City, Ohio, Pennsylvania, Virginia, and Washington.

In 2023, a total of 58 measles cases were reported by 20 U.S. jurisdictions.

In 2024, the Chicago Department of Public Health (CDPH) confirmed twelve measles cases, including an active outbreak at a local shelter in Pilsen. CDPH is coordinating a comprehensive, city-wide response to the first measles cases in Chicago in five years.

CDPH is encouraging all new arrivals to Chicago and every Chicagoan to get the measles-mumps-rubella (MMR) vaccine if they haven't already done so.

The vast majority of Chicagoans are vaccinated against measles and therefore not at high risk," said CDPH Commissioner Olusimbo 'Simbo' Ige, MD, MPH, in a press release on March 12, 2024.

"But those who are unvaccinated need to take precautions. If they're exposed, quarantine immediately and connect with their healthcare provider. Above all else, get vaccinated so you, too, can be protected from this virus."

In the U.S., MMR vaccines are available at most community pharmacies as of March 18, 2024.

Vaccine Treats: 
Image: 
Image Caption: 
US CDC measles case map March 14, 2024
Live Blog Update Author: 
Location Tags: 
Vaccine: 
Include in VBT newsletter: 
flu shot 2024
U.S. flu vaccines for 2024-2025 are three-component vaccines not four
Disease X
WHO prepares for the next virus or bacteria pandemic
0 min read

The U.S. National Center for Health Statistics (NCHS) Mortality Surveillance data available on March 14, 2024, indicates that 0.7% of the deaths that occurred during the week ending March 9, 2024 (Week 10) were due to influenza.

This percentage increased (≥ 0.1 percentage point change) compared to last week's data.

NCHS's data also confirmed that 13 influenza-associated pediatric deaths were reported to the U.S. CDC during Week 10. The total number of pediatric deaths for the 2023-2024 flu season is now 116. 

As of March 17, 2024, the CDC continues to recommend that everyone six months and older get an annual flu vaccine as long as influenza viruses are spreading. Vaccination can still provide benefits this flu season.

Various egg, cell, and nasal flu shots remain available at most community pharmacies in the U.S.

The composition of flu vaccines is reviewed annually, and new flu vaccines are manufactured each year. For the 2024-2025 flu season, many countries are transitioning to trivalent flu vaccines.

Vaccine Treats: 
Image: 
Image Caption: 
NCHS mortality surveillance data available on March 14, 2024
Live Blog Update Author: 
Location Tags: 
Include in VBT newsletter: 

Virology Explain

Virology Explained

While various agencies approve drugs and vaccines, the related terms confuse most people. Virology's unanswered questions include:

When will precision vaccines replace population-based vaccination programs and transition to personalized vaccines, targeting each person's DNA?

How does immune imprinting impact vaccination benefits?

Do vaccines eliminate or enhance virus shedding?

Package Inserts

Government agencies issued broad media statements targeting the general public, and pharmaceutical companies disclosed what is known about a vaccine in U.S. FDA Package Inserts or U.S. CDC Vaccine Information Statements (VIS). These legal disclosures ensure clinical transparency but are difficult for most people to understand. Questions regarding vaccine coadministration, use while pregnant, and efficacy are best answered when speaking with your healthcare provider. Also, Vaccine Information Sheets are written to fulfill the National Childhood Vaccine Injury Act requirement; they do not replace Informed Consent.

Informed Consent

This FDA document is structured to present general guidance on FDA's regulatory requirements for informed consent. Furthermore, since there is no Federal requirement for Informed Consent relating to immunization, your state health department must fill this void. On December 21, 2023, the FDA issued a final rule providing an exception from the requirement to obtain informed consent when a clinical investigation poses minimal risk to people and includes appropriate safeguards to protect human subjects' rights, safety, and welfare. This rule permits institutional review boards to approve an informed consent procedure that waives or alters certain informed consent elements or waives the requirement to obtain informed consent under limited conditions, specifically FDA-regulated minimal-risk clinical investigations.

Drug Vaccine Interactions

Regarding adverse drug interactions, a study published by Pediatrics in 2024 estimates that 21% of U.S. children who take prescription drugs (vaccines) will experience a severe problem from a drug-drug interaction over a year of treatment, with the risk higher among those who take more than two drugs. 

According to the U.S. CDC, adverse drug events cause approximately 1.3 million emergency department visits each year. Certain vaccines, including pneumococcal, meningococcal, and live virus vaccines, require appropriate spacing to mitigate vaccine–vaccine interactions.

2 min read
Last Reviewed: 
Sunday, March 17, 2024 - 10:30
Description: 
Drug interactions, informed consent, package inserts
Polio
National Immunization Days are a pillar of disease eradication